Healthcare, Pharma & Life Sciences

EQT Foundation Funds €1M for 11 Brain Drug-Delivery Projects

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

Clarenta Group Acquires Majority Stake in Paris-Based L2D

Image
Clarenta Group Acquires Majority Stake in Paris-Based L2D

London – September 30, 2026 -- Clarenta Group has taken a majority stake in Leads To Development (L2D), a Paris-based preclinical and regulatory consultancy, expanding its reach into early-stage drug development ahead of first-in-human trials.

Clarenta adds non-clinical and manufacturing expertise to its clinical development platform

L2D specializes in defining development pathways, assessing preclinical evidence, troubleshooting manufacturing processes, and building regulatory strategies for biotech and pharmaceutical sponsors. The addition connects this early-stage scientific work directly to Clarenta's existing Early Phase Unit and clinical consulting capabilities.

Insilico Medicine Nominates AI-Designed GIPR Antagonist ISM1354

Image
Insilico Medicine Nominates AI-Designed GIPR Antagonist ISM1354

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676
The company nominated ISM0676, a prior GIPR antagonist, in January, which showed up to 31.3% weight loss in combination with Semaglutide in humanized mouse models. ISM1354 retains comparable weight-loss efficacy while delivering improved pharmacokinetic and safety profiles, addressing tolerability issues that have derailed rival GIPR programs industry-wide.

Roche Unit Launches Triple Newborn Screening Test for SMA, SCID, SCD

Image
Roche Unit Launches Triple Newborn Screening Test for SMA, SCID, SCD

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Single kit consolidates three critical newborn screening panels for hospital labs

The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.

Simply Healthcare Foundation Gives $230K to Expand Pediatric Mental Health Program

Image
Simply Healthcare Foundation Gives $230K to Expand Pediatric Mental Health Program

Hollywood, Fla. – September 30, 2026 -- Joe DiMaggio Children's Hospital Foundation has secured a $230,000 grant from Simply Healthcare Foundation to expand New Solutions, a pediatric mental health treatment and suicide prevention program, over the next three years.

Grant funds care for 267 individuals over three years

The three-year grant began July 1 and will allow New Solutions to serve 267 individuals, targeting the gap between emergency psychiatric treatment and community-based behavioral health care. The program addresses children and adolescents who arrive at the emergency department in crisis but do not meet medical criteria for hospital admission or an involuntary examination under Florida's Baker Act.

CCAPP Merges Three Summits for 13th Annual California Addiction Conference

Image
CCAPP Merges Three Summits for 13th Annual California Addiction Conference

Los Angeles – September 30, 2026 -- The California Consortium of Addiction Programs and Professionals (CCAPP) will run its 13th Annual California Addiction Conference (CAC) from October 14-18, 2026, at the Sheraton Universal Hotel in Universal City, consolidating three previously separate summits into a single five-day program.

Vanda's HETLIOZ Hits Phase III Goal in Sleep Disorder Trial

Image
Vanda's HETLIOZ Hits Phase III Goal in Sleep Disorder Trial

Washington – September 30, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reported positive topline results from a pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD), setting up a supplemental New Drug Application (sNDA) filing with the U.S. Food and Drug Administration (FDA).

Trial meets primary endpoint with statistically significant sleep-timing shift

The study, VP-VEC-162-3502 (NCT04652882), shifted sleep onset 42.5 minutes earlier in the HETLIOZ® arm (n=20) versus 5.4 minutes on placebo (n=20), a 37.1-minute difference (p=0.022). In an exploratory responder analysis, 60% of tasimelteon-treated participants (12/20) advanced sleep onset by at least 30 minutes, compared with 15% on placebo (3/20) (p=0.008).

Lilly's Retatrutide Cuts Weight 20.8%, A1C 1.6% in Phase 3 Trial

Image
Lilly's Retatrutide Cuts Weight 20.8%, A1C 1.6% in Phase 3 Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Highest dose delivers weight loss up to 23.4% in heavier patients

Across the three tested doses, participants lost an average of 29.8 lbs (12.7%) at 4 mg, 45.4 lbs (19.1%) at 9 mg, and 49.6 lbs (20.8%) at 12 mg. Among patients with a baseline BMI of 35 or higher, the 12 mg dose produced an average loss of 60.8 lbs (23.4%), with 59.5% of all 12 mg participants no longer classified as having obesity by trial end.

Pressley Ridge Gathers 50+ Experts for W.Va. Kinship Care Summit

Bridgeport, W. Va. – September 30, 2026 -- Pressley Ridge convened more than 50 community partners, advocates, and child welfare experts at the Bridgeport Conference Center from September 15 to 18 for the B~Hope Conference and Summit, focused on advancing kinship care and family-centered support across West Virginia.

Conference spotlights two family-support frameworks

Sessions centered on the Family Centered Treatment Foundation® (FCT) model alongside the newly introduced Pressley Ridge B~Hope Embracing Kinship Caregivers curriculum, both aimed at equipping caregivers and families with practical resources to sustain kinship placements.

Home Helpers Franchisees Dow Named 2026 IFA Franchisee of the Year

Cincinnati – September 30, 2026 -- Beth and Phillip Dow, franchisees of Home Helpers Home Care in Newnan, Georgia, have been named 2026 Franchisee of the Year by the International Franchise Association, an honor they also received in 2015.

Newnan franchise projects $4.5 million in revenue for 2026

The Dows' operation, now in its 19th year, employs 150 caregivers and 14 operations staff serving 112 clients. The award was presented during the IFA26 Advocacy Summit in Washington, D.C., held Sept. 14-16, with a formal luncheon on Sept. 15.

Franchisees expand into Canton, Georgia market

Last month the Dows opened Home Helpers Home Care of Canton, Georgia, extending their footprint beyond the original Newnan territory ahead of their 20th anniversary with the brand next year.